Publications by authors named "Tyler J Roady"
Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However, the relationship between disease severity and the repertoire of antibodies against specific SARS-CoV-2 epitopes an individual develops following exposure remains incompletely understood. Here, we studied seroprevalence of antibodies to specific SARS-CoV-2 and other betacoronavirus antigens in a well-annotated, community sample of convalescent and never-infected individuals obtained in August 2020.
View Article and Find Full Text PDFBackground: To facilitate deployment of point-of-care testing for severe acute respiratory syndrome coronavirus 2, we evaluated the Access Bio CareStart COVID-19 Antigen test in a high-throughput, drive-through, free community testing site using anterior nasal (AN) swab reverse-transcription polymerase chain reaction (RT-PCR) for clinical testing.
Methods: Consenting symptomatic and asymptomatic children (≤18 years) and adults received dual AN swabs. CareStart testing was performed with temperature/humidity monitoring.
Article Synopsis
- Rapid diagnostic tests (RDTs) for SARS-CoV-2, like the Abbott BinaxNOW, can enhance COVID-19 testing at point of care by providing quick results alongside traditional molecular tests.
- A study in Massachusetts evaluated the effectiveness of BinaxNOW by comparing its results with standard PCR tests among both symptomatic and asymptomatic individuals, covering over 2,400 participants.
- The findings showed high sensitivity (96.5% for adults and 84.6% for children with symptoms) and excellent specificity (100% for both groups), but lower sensitivity for asymptomatic individuals (70.2% for adults and 65.4% for children).